Prosecution Insights
Last updated: April 19, 2026
Application No. 17/908,434

IONTOPHORETIC COMPOSITION FOR ADMINISTERING S-KETAMINE

Final Rejection §112
Filed
Aug 31, 2022
Examiner
OTTON, ALICIA L
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
LTS LOHMANN THERAPIE-SYSTEME AG
OA Round
2 (Final)
65%
Grant Probability
Moderate
3-4
OA Rounds
2y 9m
To Grant
74%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allow Rate
817 granted / 1260 resolved
+4.8% vs TC avg
Moderate +9% lift
Without
With
+9.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
32 currently pending
Career history
1292
Total Applications
across all art units

Statute-Specific Performance

§101
1.3%
-38.7% vs TC avg
§103
24.5%
-15.5% vs TC avg
§102
24.9%
-15.1% vs TC avg
§112
28.8%
-11.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1260 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The information disclosure statement (IDS) dated December 2, 2025 was in compliance with the provisions of 37 CFR 1.97 and 1.98. Accordingly, the IDS document was considered and a signed copy of the 1449 form is attached. Response to Remarks and Amendments Applicant’s reply filed November 28, 2025 has been entered. All rejections and objections not explicitly maintained herein are withdrawn. With regard to the rejection of claims 1-20 under 35 USC 103 as being unpatentable over Varenna in view of WO 2019/121293 and WO 2007/124,358 Applicants traverse the rejection in view of the claim amendment requiring a particular range of ionic strength for the claimed composition. The examiner agrees that Varenna teaches an ionic strength of NaCl of 0.05 mol/L and does not contain any suggestion to increase the ionic strength to a value falling within the instantly claimed range, as amended. Accordingly, the rejection is withdrawn. Status of Claims Claims 1-20 remain pending and under consideration herein. Claim Rejections – 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 3 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 3 recites the limitation that the composition contains cations which are not due to protonated ketamine in a concentration in the range of from about 0.05 to about 1.5 mol/L. Such is claimed as an alternative to the ionic strength being from 0.1 to about 1.0 mol/L. The claimed limitation falls outside the scope of what is encompassed by claim 1 since cation concentration not due to protonate ketamine falling under 0.1 mol/L falls outside the range of ionic strength encompassed by the independent claim. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Conclusion Claims 1-2 and 4-20 are allowed Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alicia L. Otton whose telephone number is (571)270-7683. The examiner can normally be reached on Monday - Thursday, 8:00-6:00. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mr. Fereydoun Sajjadi can be reached on 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ALICIA L OTTON/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Aug 31, 2022
Application Filed
Aug 23, 2025
Non-Final Rejection — §112
Nov 28, 2025
Response Filed
Mar 19, 2026
Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600701
N-ACYLHYDRAZONIC COMPOUNDS, USE IN THE TREATMENT OF AMYLOID AND NON-AMYLOID DEGENERATIVE AGGREGOPATHIES, AND PHARMACEUTICAL COMPOSITION
2y 5m to grant Granted Apr 14, 2026
Patent 12600709
NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12588678
OXAZOLINE COMPOUND, SYNTHESIS METHOD THEREFOR AND APPLICATION THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12583887
PSMA Imaging Agents
2y 5m to grant Granted Mar 24, 2026
Patent 12583840
METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
65%
Grant Probability
74%
With Interview (+9.1%)
2y 9m
Median Time to Grant
Moderate
PTA Risk
Based on 1260 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month